CoChat

Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease

Open access

The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index; 93 of the 168 sources its claims cite were checked for support.

Abstract

Different types of engineered nanoparticles have been demonstrated to be able to penetrate this barrier and serve as efficient drug delivery systems into the brain, making them a promising solution for future therapeutic development.

Overview

CoChat Summary

## TL;DR

This is a narrative review of nanoparticle-based strategies to move drugs across the blood–brain barrier for Alzheimer’s disease, with emphasis on surface functionalization, focused ultrasound, stimuli-responsive systems, exosomes, gene therapy, and magnetic nanoparticles. It concludes that these approaches are promising in preclinical studies but have not yet achieved clinical translation for AD.

## Key findings

  • The review states that the blood–brain barrier is the main obstacle to AD drug delivery, and that engineered nanoparticles can improve targeting, loading capacity, bioavailability, and reduce systemic adverse effects.
  • It identifies several strategies to enhance brain delivery: surface-functionalized nanoparticles, focused ultrasound (FUS) combined with microbubbles, stimuli-responsive nanoparticles, gene-therapy nanoparticles, exosome-mediated delivery, and magnetic nanoparticles.
  • For physicochemical design, it reports that nanoparticles for brain delivery are generally considered suitable in the 100–200 nm range; very small particles (<30 nm) may be renally cleared, while larger ones (150–300 nm) may accumulate in liver and spleen.
  • The paper notes that despite multiple encouraging preclinical examples, clinical application in trials is “nonexistent” for these advanced nanoparticle strategies in AD, and that only one brain-targeted nanoparticle therapy is approved overall (NanoTherm®, for brain cancer), not AD.

## Methods

  • This is a review article, not an original experimental study.
  • The authors report a comprehensive literature search using PubMed and Google Scholar, with keywords including nanoparticles, Alzheimer’s disease, in vitro studies, in vivo studies, encapsulated drug, surface functionalization, stimuli-responsive, focused ultrasound, and magnetic nanoparticles.
  • They selected articles published preferably after 2020, requiring in vitro and/or in vivo studies, direct investigation of the BBB and/or AD, and positive or relevant experimental results.

## Limitations

  • The paper states that many approaches remain limited by clinical translation barriers, including long-term safety, chronic toxicity, immunogenicity, quality control in large-scale production, regulatory hurdles, pricing, and off-target effects.
  • It also states that animal models do not fully reproduce human AD, and that mice and rats “neither naturally nor experimentally induced develop AD” in the same way as humans; this limits translation to patients.
  • Evident from the text: the article is a narrative review rather than a systematic review or meta-analysis, so the evidence synthesis is broader and less standardized than a formal systematic method.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph19050685

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Main components of the BBB. This image was created with the software Canvas (https://www.canva.com/).
Figure 1 Main components of the BBB. This image was created with the software Canvas (https://www.canva.com/).CC BY · PubMed Central
Figure 2 Potential pathways across the BBB. This image was created with the software Canvas (https://www.canva.com/).
Figure 2 Potential pathways across the BBB. This image was created with the software Canvas (https://www.canva.com/).CC BY · PubMed Central
Figure 3 Scheme of types of molecules commonly used for NP surface modification. This image was created with the software Canvas (https://www.canva.com/). Tf and albumin structures (pdb_00001a8e and pdb_00001ao6, respectively) were retrieved from RCSB PDB (https://www.rcsb.org/).
Figure 3 Scheme of types of molecules commonly used for NP surface modification. This image was created with the software Canvas (https://www.canva.com/). Tf and albumin structures (pdb_00001a8e and pdb_00001ao6, respectively) were retrieved from RCSB PDB (https://www.rcsb.org/).CC BY · PubMed Central
Figure 4 Exosome’s structure. Adapted from [112,113]. This image was created with the software Canvas (https://www.canva.com/).
Figure 4 Exosome’s structure. Adapted from [112,113]. This image was created with the software Canvas (https://www.canva.com/).CC BY · PubMed Central

Verification

Claims the paper makes

87 Valid · 3 Not valid · 56 Not checked · 33 Own results and interpretations

60 more claims · 28 with their cited sources checked

Create a free account to see all 179 claims and to verify the 23 references still open.

See all claims — free account
  • Probably not a substantial claim. 45
  • It may state two separate claims as one. 88

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 4

  1. Dotiwala, A.K., McCausland, C., and Samra, N.S. (2025, October 01). Anatomy, Head and Neck: Blood Brain Barrier, Available online: https://www.ncbi.nlm.nih.gov/books/NBK519556/.
  2. (2026, April 17). Polymer Nanoparticles—An Overview|ScienceDirect Topics. Available online: https://www.sciencedirect.com/topics/materials-science/polymer-nanoparticles.
  3. Zhang, 2024, Multifunctional mesoporous nanoselenium delivery of metformin breaks the vicious cycle of neuroinflammation and ROS, promotes microglia regulation and alleviates Alzheimer’s disease, Colloids Surf. B Biointerfaces, 245, 114300
  4. Mutluay, 2022, Donepezil-loaded PLGA-b-PEG Nanoparticles Enhance the Learning and Memory Function of Beta-Amyloid Rat Model of Alzheimer’s Disease, Arch. Neuropsychiatry, 59, 281

Cited by

See all 2

Metadata

Authors
Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C.
Affiliations
Universidade do Porto (PT)
Corresponding author
  • Loureiro, Joana A.
  • Pereira, Maria Carmo
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2026-04-27
Volume
19
Issue
5
Pages
685
ISSN
1424-8247 (ISSN-L)
OpenAlex
W7160150054
Cited by
2
References
126
Citations by year
2026: 2
FWCI
0.87
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • FCT/MCTES (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020)
  • Foundation for Science and Technology (M-ERA-NET3/0001/2021)
  • Project Nano4Glio (958174)
  • European Union (NORTE2030-FEDER-02696100)
  • FCT (CEEC-IND/01741/2021)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
Alzheimer's disease, blood-brain barrier, engineered nanoparticles, nanoparticle drug delivery, brain drug delivery, clinical translation barriers, neurodegenerative disease treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.